PHASQ PhaseBio Pharmaceuticals (PNK) down 99.00% 06 Feb 2026: top loser insights

PHASQ stock collapsed during market hours on 06 Feb 2026, trading at USD 0.000001 and down 99.00% on the day on the PNK exchange in the United States. Volume was light at 2,500 shares versus an average of 22,310, while the one‑year high sits at USD 0.03990. This move places PhaseBio Pharmaceuticals, Inc. (PHASQ) among the session’s top losers as investors react to end‑stage restructuring and delisting risk. We examine the drivers, financials, and what scenarios could matter next for traders tracking PHASQ stock.

Price action and trading snapshot for PHASQ stock

PHASQ stock is quoted at USD 0.000001 on the PNK exchange in the United States, with a one‑day decline of 99.00%. The intraday range held at the record low USD 0.000001 and previous close was USD 0.00010. Volume of 2,500 shares represented a relative volume of 0.11 versus a 50‑day average price of USD 0.000236 and 200‑day average of USD 0.000666. This narrow trading pattern and sub‑penny price indicate extreme liquidity and market microstructure risk for PHASQ trading.

Key fundamentals and valuation metrics for PHASQ stock

PhaseBio shows clinical‑stage biotech metrics: trailing EPS -2.14 and a negative PE reflecting no earnings. Cash per share is USD 1.42, while book value per share is negative USD -3.16, and enterprise value is reported as -33,955,000.00. The current ratio is 1.75 and interest coverage is 137.72, but free cash flow per share is USD -1.70. These figures point to persistent operating losses and balance sheet stress tied to Chapter 11 reorganization history and development spending.

Catalysts and risks driving PHASQ stock movement

Regulatory and listing status remain primary catalysts: PhaseBio filed Chapter 11 in 2022 and market commentary marks the company as potentially delisted, which heightens downside pressure on PHASQ stock. Clinical readouts for PB2452 and PB1046 would be material positive catalysts, but dilution, low liquidity, and potential delisting are immediate risks. Sector backdrop in Healthcare and Biotechnology shows selective strength, but PHASQ’s microcap status isolates it from sector inflows.

Technical and liquidity view: what traders should watch on PHASQ stock

Technically, PHASQ stock trades well below its 50‑day average USD 0.000236 and 200‑day average USD 0.000666, signaling a collapsed trend. Average daily volume is 22,310 but today’s traded 2,500 shares suggest limited market participation and high spread risk. For active traders, watch bid/ask size, pattern of restrained prints, and any change in exchange status filings that will immediately affect tradability.

Meyka AI grade and scenario price targets for PHASQ stock

Meyka AI rates PHASQ with a score of 62.91 out of 100 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Scenario price targets: Bear USD 0.0000 (delisting or zero recovery), Base USD 0.0001 (minimal recovery, continued microcap trading), Bull USD 0.0200 (clinical success and recapitalization). These are scenario estimates, not analyst price targets, and carry high probability variance.

Final Thoughts

PHASQ stock is a top loser in today’s market hours, trading at USD 0.000001 and down 99.00% on 06 Feb 2026 on the PNK exchange in the United States. The price collapse reflects thin liquidity, potential delisting risk, and ongoing restructuring dynamics. Meyka AI’s forecast model projects a 12‑month target of USD 0.00, which compares to the current quote and implies an effective downside near 100.00% from today’s level; forecasts are model‑based projections and not guarantees. Traders should prioritize exchange filings, cash runway signals, and any clinical or restructuring news that could change recoverability. Given the profile, our scenario framework (Bear USD 0.0000, Base USD 0.0001, Bull USD 0.0200) frames asymmetric outcomes but stresses high risk and potential for total loss. Use tight risk controls, confirm tradability before sizing positions, and consult multiple sources before acting. Meyka AI provides this as AI‑powered market analysis and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.